• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    All News #Library
    Others

    Abbvie Seeks Oncology Pipeline Respect Post Remegen Acquisition

    BIOSPACE

    RemeGen, Santen ink exclusive deal for ophthalmic RC28-E Drug

    PR NEWSWIRE

    Telitacicept Ph III Succeeds in Primary Sjögren’s Syndrome

    PR NEWSWIRE

    RemeGen Completes IgA Nephropathy, Sjögren`s Phase 3 Enrollment

    PR NEWSWIRE

    RemeGen Shares Lupus Knowledge On World Lupus Day 2024

    PR NEWSWIRE

    World Cancer Day 2024: RemeGen Announces Three Significant Developments

    PR NEWSWIRE

    RemeGen`s RC88 Obtained FDA Fast Track Designation

    PR NEWSWIRE

    RemeGen Shows Profitability to Receive Approval from Hong Kong Stock Exchange

    PR NEWSWIRE

    RemeGen Celebrates World Intellectual Property Day 2023

    PR NEWSWIRE

    RemeGen`s RC118 for Injection Granted Two Orphan Drug Designations by FDA

    PRNEWSWIRE

    RemeGen Biosciences to Attend ASN Kidney Week 2022

    PRNEWSWIRE

    RemeGen Releases Phase II Study Data for Treatment of Myasthenia Gravis

    PRNEWSWIRE

    RemeGen receives ODD for myasthenia gravis treatment

    EUROPEANPHARMACEUTICALREVIEW

    RemeGen Receives Orphan Drug Designation from FDA for Telitacicept

    PRNEWSWIRE

    RemeGen Announces Results of PIII Study of Telitacicept

    PRNEWSWIRE

    RemeGen Commemorates International Self-Care Day with Health Initiatives

    PRNEWSWIRE

    RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO

    ASIAONE

    Regulatory roundup: AbbVie’s Phase II fail plunges Alzheimer’s contender’s shot

    CLINICALTRIALSARENA

    Seagen undaunted by AstraZeneca-Daiichi`s Enhertu

    FIERCEPHARMA

    Seagen bets up to $2.6B on China’s first homemade ADC

    FIERCEPHARMA

    ADC experts at Seagen find a $2.6B HER2 gem in China

    ENDPTS

    USFDA Breakthrough Therapy Designation for RemeGen`s Disitamab Vedotin (RC48)

    PRESS RELEASE

    RemeGen Announces US FDA Clearance of IND Application to Initiate Phase II trial

    PR NEWSWIRE

    FDA Grants Fast Track Designation to RemeGen`s Telitacicept

    PR NEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.